Lattice Semiconductor (LSCC) Holder State Street Has Raised Position; As Illumina (ILMN) Share ...
"... OF TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 10/04/2018 – ILLUMINA – CO-DEVELOPMENT PARTNERSHIP ..."
Published: Oct 12th, 2019 12:22 AM
A pain in the neck
"Two other kinds of thyroid cancer - medullary and undifferentiated, which are extremely rare in that they make for less than one per cent of all thyroid ..."
Published: Oct 11th, 2019 4:43 PM
Investment Counselors Of Maryland Has Decreased Brady Cl A (BRC) Stake by $5.29 Million ...
"... ILLUMINA TRUSIGHT TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 29/05/2018 – Illumina at ..."
Published: Oct 11th, 2019 4:20 PM
How Analysts Rated Eli Lilly and Company (NYSE:LLY) Last Week?
"... (NYSE:LLY) news were published by: Prnewswire.com which released: "Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) ..."
Published: Oct 11th, 2019 11:57 AM
EPS for Illumina, Inc. (ILMN) Expected At $1.41; LENOVO GROUP LTD ORDINARY SHARES ...
"$4.59; 10/04/2018 – LOXO ONCOLOGY-PARTNERSHIP TO SEEK ... AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS ..."
Published: Oct 10th, 2019 6:00 PM
As Illumina (Put) (ILMN) Share Value Declined, Bank Of Montreal Has Trimmed Holding; Alibaba ...
"... ILLUMINA TRUSIGHT TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 13/04/2018 – ILLUMINA ..."
Published: Oct 10th, 2019 2:37 PM
Lung Cancer Therapy Makes Major Advances
"At the World Conference on Lung Cancer, we saw results with LOXO-292 in a cohort of approximately 105 patients with RET-positive lung cancer."
Published: Oct 10th, 2019 12:52 PM
Illumina (ILMN) Holding Has Boosted by Roundview Capital Llc; Arga Investment Management LP ...
"... 10/04/2018 – LOXO ONCOLOGY – COMPANIES ALSO PLANNING TO ... TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 ..."
Published: Oct 10th, 2019 12:00 PM
Precision oncology: Exciting clinical developments and complicated biology
"Drilon and colleagues presented results from the LIBRETTO clinical study of selpercatinib (LOXO-292, Loxo Oncology) in September at International ..."
Published: Oct 10th, 2019 10:18 AM
Analysts See $5.13 EPS for Regeneron Pharmaceuticals, Inc. (REGN); Orbimed Advisors ...
"... COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 09/05/2018 – CAREDX IN LICENSE & COMMERCIALIZATION ..."
Published: Oct 10th, 2019 9:56 AM
Medullary Thyroid Cancer Treatment Market 2019-2026: Global Industry Trends, Analysis, Share ...
"Medullary Thyroid Cancer Treatment Market 2019 Global Market Research report presents an in-depth analysis of the Medullary Thyroid Cancer ..."
Published: Oct 9th, 2019 1:14 PM
Illumina (ILMN) Stake Maintained by Ngam Advisors Lp; Credit Agricole SA Upped Its Stake in ...
"... AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 23/04/2018 – DJ Illumina Inc, Inst Holders, 1Q 2018 (ILMN); ..."
Published: Oct 9th, 2019 9:56 AM
As Lowes Cos (LOW) Share Price Declined, Holder Nj State Employees Deferred Compensation ...
"... TRUSIGHT TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 24/04/2018 – ILLUMINA INC ILMN."
Published: Oct 9th, 2019 4:18 AM
Weekly Investment Analysts' Ratings Changes for Blueprint Medicines (BPMC)
"By 2020, the company expects to have two marketed products in the United States - avapritinib and BLU-667. However, in the absence of a marketed ..."
Published: Oct 9th, 2019 12:11 AM
Coverage Initiated on US-Based Precision Therapy Developer
"... new drug applications for avapritinib for treatment of advanced systemic mastocytosis and pralsetinib (BLU-667) for secondline RET fusion nonsmall ..."
Published: Oct 9th, 2019 12:11 AM
Coverage Initiated on US-Based Precision Therapy Developer
"... pointed out that H.C. Wainwright and key opinion leaders view the market opportunities for both avapritinib and pralsetinib to be "underappreciated."
Published: Oct 8th, 2019 8:03 PM
Winslow Capital Management Continues to Hold Position in Illumina (ILMN); As Unitedhealth ...
"... LOXO-292 ACROSS TUMORS; 02/05/2018 – Illumina to Webcast Upcoming Investor Conference Presentation; 25/04/2018 – ILLUMINA INC ILMN."
Published: Oct 8th, 2019 5:26 PM
Teradata (TDC) Reaches $29.00 1 Year Low; Hitchwood Capital Management LP Raised Its ...
"$1.02; 10/04/2018 – ILLUMINA INC – LOXO ONCOLOGY TO UTILIZE A ... AND LOXO-292 (RET); 15/05/2018 – Illumina Acquired Edico Genome."
Published: Oct 8th, 2019 3:48 PM
Illumina, Inc. (ILMN) Reaches $290.36 After 8.00% Down Move; Servotronics (NYSEAMERICAN ...
"... LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 29/03/2018 – SiriusDecisions Recognizes Cisco, Huron Consulting Group, Illumina, Imprivata and ..."
Published: Oct 8th, 2019 3:22 PM
FDA awards two grants for natural history studies in rare diseases
"University of Texas MD Anderson Cancer Center (Houston, Texas), Elizabeth Grubbs, prospective study in medullary thyroid carcinoma, ..."
Published: Oct 8th, 2019 2:58 PM
Analysts See $-2.17 EPS for Blueprint Medicines (BPMC); Franklin Resources Has Cut Its Nike ...
"... Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients ..."
Published: Oct 7th, 2019 9:33 PM
Df Dent & Co Holds Stake in Illumina (ILMN); As Cyrusone (CONE) Valuation Rose, Shareholder ...
"$782M; 10/04/2018 – LOXO ONCOLOGY-PARTNERSHIP TO SEEK ... AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS ..."
Published: Oct 7th, 2019 3:08 PM
Capital International Has Trimmed Its Avon Products (AVP) Position by $361200 as Share Price ...
"... TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 15/05/2018 – Illumina Acquired Edico Genome ..."
Published: Oct 7th, 2019 2:48 PM
As Merck & Co. (MRK) Valuation Rose, Coho Partners LTD Has Cut by $4.98 Million Its Stake; Cam ...
"... COMPANION DIAGNOSTIC VERSION OF TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 23/04/2018 – DJ Illumina ..."
Published: Oct 7th, 2019 2:25 PM
Tokio Marine Asset Management Co LTD Has Increased Position in Gilead Sciences (GILD) as ...
"... (NTRK) AND LOXO-292 (RET); 24/04/2018 – ILLUMINA INC ILMN.O SEES FY 2018 REVENUE UP 15 TO 16 PCT; 10/04/2018 – Illumina and Loxo ..."
Published: Oct 7th, 2019 1:18 PM
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
"... identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292."
"Types of neuroendocrine tumors are islet cell tumors, carcinoid tumors, pheochromocytomas, medullary thyroid cancer, neuroendocrine carcinoma, ..."
Published: Oct 7th, 2019 4:16 AM
Medullary Thyroid Cancer Occurrence Population, Disease Trends, Epidemiology-Based ...
"Report Ocean, "Medullary Thyroid Cancer -Epidemiology Forecasting Intelligence" This report gives a detailed overview of the XYZ epidemiology and ..."
"Report Ocean, "Medullary Thyroid Cancer The study provides an overview of Medullary Thyroid Cancer disease and market size for the seven major ..."
Published: Oct 6th, 2019 7:48 PM
Capital World Investors Raised Illumina (ILMN) Stake; Vuzix (VUZI) Sentiment Is 0.79
"... OF TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 24/04/2018 – ILLUMINA INC ILMN.O FY2018 SHR VIEW $4.59, ..."
Published: Oct 6th, 2019 5:37 PM
Jaffetilchin Investment Partners Boosted Boeing Co (BA) Stake by $771738 as Market Value ...
"... LAROTRECTINIB (NTRK) AND LOXO-292 (RET). Jaffetilchin Investment Partners Llc increased its stake in Boeing Co (BA) by 193.27% based on its ..."
Published: Oct 6th, 2019 3:33 PM
SR Schill & Associates Trimmed Holding in Medical Pptys Trust Com (MPW) by $4.97 Million as ...
"Some Historical ILMN News: 10/04/2018 – ILLUMINA INC – LOXO ... AND LOXO-292 (RET); 30/05/2018 – Designer babies are just one example of ..."
Published: Oct 6th, 2019 2:42 PM
Comparing of Spectrum Pharmaceuticals Inc. (SPPI) and Exelixis Inc. (NASDAQ:EXEL)
"... including FUSILEV for patients with metastatic colorectal cancer and rescue ... of patients with progressive, metastatic medullary thyroid carcinoma."
Published: Oct 6th, 2019 2:15 PM
$-2.17 EPS Expected for Blueprint Medicines (BPMC); Driehaus Capital Management Has ...
"Some Historical BPMC News: 15/04/2018 – $BPMC #AACR18 BLU-667 RETi data out; 26/04/2018 – DUNKIN' BRANDS GROUP INC – 2018 ..."
Published: Oct 6th, 2019 10:17 AM
First Financial Cut Position in Verizon Communications (VZ) by $569715; Illumina (ILMN ...
"... 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 15/05/2018 – Illumina: Edico's DRAGEN Bio-IT Platform ..."
Published: Oct 5th, 2019 5:37 PM
Oz Management LP Holds Stake in Illumina (ILMN); Ironwood Investment Counsel Has Raised Its ...
Cme Group (CME) Share Price Rose While Mizuho Bank LTD Trimmed by $179.00 Million Its ...
"... TRUSIGHT TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 13/04/2018 – Bristol-Myers Squibb ..."
Published: Oct 4th, 2019 9:22 PM
Exelixis Inc. (EXEL) Plunges 5.02% on October 04
"Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell ..."
Published: Oct 4th, 2019 4:30 PM
At ESMO, more precision medicines show their worth
"As Ms White explains, an early analysis of data from treatment-naïve patients showed that: "selpercatinib treatment resulted in a 59% ORR, with no ..."
Published: Oct 4th, 2019 4:30 PM
At ESMO, more precision medicines show their worth
"... test group, people with RET-mutant medullary thyroid cancer who had previously received Cometriq (cabozantinib) and/or Caprelsa (vandetanib)."
Published: Oct 4th, 2019 4:30 PM
At ESMO, more precision medicines show their worth
"... (ESMO), one of the more eagerly anticipated presentations focused on former Loxo Oncology candidate selpercatinib (LOXO-292), a RET inhibitor."
Published: Oct 4th, 2019 3:32 PM
Precision Medicine for RET Fusion–Positive NSCLC
"Selpercatinib (LOXO-292), a RET kinase inhibitor, demonstrated antitumor activity in the lungs and brain and durable responses with acceptable ..."
Published: Oct 4th, 2019 11:14 AM
Illumina, Inc. (ILMN) Analysts See $1.41 EPS; Shorts at NUVISTA ENERGY LTD ORDINARY ...
"... COMPANION DIAGNOSTIC VERSION OF TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 29/05/2018 – Illumina at ..."
Published: Oct 4th, 2019 11:03 AM
Hitchwood Capital Management LP Has Increased Illumina (ILMN) Holding; As Intercontinental ...
"... TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 08/05/2018 – CAREDX INC – ON MAY 4, 2018 ..."
Published: Oct 4th, 2019 7:52 AM
$0.18 EPS Expected for Exelixis, Inc. (EXEL)
"... have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma."
Published: Oct 3rd, 2019 7:10 PM
Boeing Co (BA) Holder Perkins Coie Trust Company Lifted Stake by $496584 as Valuation ...
"... Fool" on September 17, 2019, also Prnewswire.com with their article: "Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in ..."
Published: Oct 3rd, 2019 4:09 PM
Newell Brands Inc. (NWL) Analysts See $0.56 EPS; Cqs Cayman LP Has Decreased Illumina ...
"... TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 10/04/2018 – LOXO ONCOLOGY – COMPANIES ALSO PLANNING ..."
Published: Oct 3rd, 2019 4:07 PM
Illumina (ILMN) Position Maintained by Guardian Capital Advisors Lp; As Costco Companies ...
"... LOXO-292 ACROSS TUMORS; 13/04/2018 – BRISTOL-MYERS SQUIBB CO – EXPANDS ILLUMINA'S ONCOLOGY OFFERINGS FOR NEXTSEQ ..."
Published: Oct 3rd, 2019 3:11 PM
Shareholder Wedbush Securities Has Raised Illumina (ILMN) Stake; Valero Energy New (VLO ...
"... TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 09/05/2018 – CareDx expands NGS Transplant Product Offerings; ..."
Published: Oct 3rd, 2019 2:09 PM
Here's Why You Should Add Thermo Fisher to Your Portfolio
"... identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients, who may be treated with Lilly's investigational therapy, LOXO-292."
Published: Oct 3rd, 2019 11:15 AM
UPDATE: HC Wainwright Starts Blueprint Medicines (BPMC) at Buy
"... suitable for long-term treatment; (3) while LOXO-292 has previously been perceived as the best-in-class RET inhibitor, physician feedback suggests ..."
Published: Oct 3rd, 2019 11:09 AM
UPDATE: HC Wainwright Starts Blueprint Medicines (BPMC) at Buy
"... NDA submissions for avapritinib in advanced systemic mastocytosis (AdvSM) and pralsetinib (BLU-667) in 2L RET-fusion non-small cell lung cancer ..."
Published: Oct 2nd, 2019 10:30 PM
Medullary Thyroid Cancer 2019 Drug Overview, Therapeutic Assessment, Pipeline Analysis ...
"Report Ocean, "Medullary Thyroid Cancer, 2019", This Mechanism of Action (MoA) offers extensive perspectives on pipeline drugs. The report's main ..."
Published: Oct 2nd, 2019 10:15 PM
Wallace Capital Management Decreased Holding in White Mtns Ins Group LTD (WTM) by $1.12 ...
"... FOR VERSION OF ILLUMINA TRUSIGHT TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS."
Published: Oct 2nd, 2019 10:15 PM
Reviewing ImmunoCellular Therapeutics Ltd. (IMUC)'s and Exelixis Inc. (NASDAQ:EXEL)'s results
"... and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived ..."
Published: Oct 2nd, 2019 9:45 PM
Medullary Thyroid Cancer Market Assessment, Market Opportunities, Market Insight, Patent Data ...
As Microsoft (MSFT) Stock Rose, Holder Adams Asset Advisors Trimmed Its Stake by $690137 ...
"... TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 29/05/2018 – Illumina to Webcast Upcoming Investor Conference Presentations ..."
Published: Oct 2nd, 2019 6:56 PM
Eli Lilly and Company's (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 ...
"... mutations occur in approximately 60% of sporadic medullary thyroid cancer, ... As you recall, data in RET fusion positive non-small cell lung cancer ..."
Published: Oct 2nd, 2019 5:37 PM
Tekla Capital Management Cut Illumina (ILMN) Stake by $14.37 Million; Tiverton Asset ...
"... DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 29/03/2018 – SiriusDecisions Recognizes Cisco, Huron Consulting Group, ..."
Published: Oct 2nd, 2019 4:57 PM
Orbimed Advisors Lowered Its Illumina (ILMN) Stake by $32.05 Million as Stock Declined; Tygh ...
"... FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 09/05/2018 – CareDx Enters Into License and Commercialization Agreement With Illumina; ..."
Published: Oct 2nd, 2019 3:56 PM
BioIndiana Hotbed: Home to a Thriving Biopharma Industry
"One of the assets, LOXO-292, hit the mark as a monotherapy for the treatment of RET fusion-positive non-small cell lung cancer in a Phase I/II trial."
Published: Oct 2nd, 2019 1:57 PM
Danaher (DHR) Shareholder Allen Investment Management Has Cut Holding as Stock Price Rose ...
"... DIAGNOSTIC VERSION OF TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 13/04/2018 – BRISTOL-MYERS – COS ..."
Published: Oct 2nd, 2019 1:11 PM
As Illumina (ILMN) Shares Declined, Wellington Shields & Company Has Decreased Stake by ...
"... TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 15/05/2018 – Illumina Acquires Edico Genome ..."
Published: Oct 2nd, 2019 10:52 AM
The Alliance for Regenerative Medicine Announces Election of 2020 ARM Officers, Executive ...
"WASHINGTON, D.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the international ..."
Published: Oct 2nd, 2019 1:27 AM
Selpercatinib in RET Fusion–Positive Thyroid Cancer
"Selpercatinib (previously known as LOXO-292) is an oral and selective investigational new agent that is being evaluated for the treatment of patients ..."
Published: Oct 1st, 2019 5:37 PM
Penn spinoff licenses experimental cancer immunotherapy from CHOP
"Penn spinoff Tmunity Therapeutics Inc. has entered into an exclusive license and research collaboration agreement with Children's Hospital of ..."
Published: Oct 1st, 2019 10:52 AM
Tmunity Announces Exclusive License and Research Collaboration with Children's Hospital of ...
"Collaboration broadens Tmunity's pipeline of pediatric oncology therapies. - Expansion potential into other hard-to-treat solid tumors."
Published: Sep 30th, 2019 11:48 PM
Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib
"The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292."
Published: Sep 30th, 2019 11:48 PM
Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib
"The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292."
Published: Sep 30th, 2019 12:22 PM
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for ...
"... of wildtype and mutated RET kinases as compared to proxy chemical compounds for investigational RET inhibitors, LOXO-292 and BLU-667."
Published: Sep 30th, 2019 12:22 PM
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for ...
"... of wildtype and mutated RET kinases as compared to proxy chemical compounds for investigational RET inhibitors, LOXO-292 and BLU-667."
Published: Sep 30th, 2019 10:47 AM
Eli Lilly Says Selpercatinib Shows 'Demonstrative Efficacy and Safety' in RET-Altered Thyroid ...
"In the RET-mutant medullary thyroid cancer population, selpercatinib achieved a 56% overall response rate (ORR) in patients who had prior treatment ..."
Published: Sep 30th, 2019 10:47 AM
Eli Lilly Says Selpercatinib Shows 'Demonstrative Efficacy and Safety' in RET-Altered Thyroid ...
"Drug maker Eli Lilly and Co. (LLY) said Monday that data from its registrational Libretto-001 thyroid cancer trial of selpercatinib showed "demonstrative ..."
Published: Sep 30th, 2019 9:50 AM
Vantage Esmo 2019 roundup
"Thyroid results strengthen selpercatinib's case. 29 September. As selpercatinib confirms its activity in thyroid cancer, Lilly gears up to prove the Ret ..."
Published: Sep 30th, 2019 5:37 AM
Medullary Thyroid Cancer Drugs Market Comprehensive Study with Key Trends, Major Drivers and ...
"Market Study Report LLC has added a new report on Medullary Thyroid Cancer Drugs Market Size that provides a comprehensive review of this ..."
Published: Sep 30th, 2019 5:15 AM
Gemma Collins' weight loss jabs - the risks of the hunger fighting injections revealed
"However, it adds: "It is not known if Victoza will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people."."
Published: Sep 29th, 2019 6:56 PM
Selpercatinib Demonstrates Robust ORR in Thyroid Cancer
"Selpercatinib Demonstrates Robust ORR in Thyroid Cancer ... selpercatinib (formally LOXO-292) in patients with RET-mutant medullary thyroid cancer ..."
Published: Sep 29th, 2019 6:56 PM
Selpercatinib Demonstrates Robust ORR in Thyroid Cancer
"Strong objective responses rates were seen in the phase I/II LIBRETTO trial, which studied RET inhibition with selpercatinib (formally LOXO-292) in ..."
Published: Sep 29th, 2019 5:36 PM
Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected
"The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates (ORR) for patients with ..."
Published: Sep 29th, 2019 5:36 PM
Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected
"Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission ... (ORR) for patients with RET-mutant medullary thyroid cancer (MTC) and for ..."
Published: Sep 29th, 2019 5:36 PM
Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected
"The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates (ORR) for patients with ..."
Published: Sep 29th, 2019 2:26 PM
ESMO: Lilly's RET drug shrinks more than half of rare thyroid cancers
"It's a different conversation with non-medullary thyroid cancers: "They are more molecularly diverse in a way that is helpful to our story. Today, BRAF ..."
Published: Sep 29th, 2019 2:26 PM
Lilly (LLY) Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily ...
"In the RET-mutant MTC registration dataset consisting of the first 55 enrolled patients with prior cabozantinib and/or vandetanib2, selpercatinib ..."
Published: Sep 29th, 2019 2:26 PM
Lilly (LLY) Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily ...
"RET-altered thyroid cancers are comprised of two different populations, RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid ..."
Published: Sep 29th, 2019 2:26 PM
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated ...
"56 percent objective response rate (ORR) in the registration dataset (n=55) of RET-mutant medullary thyroid cancer (MTC) patients who had ..."
Published: Sep 29th, 2019 2:26 PM
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated ...
"56 percent objective response rate (ORR) in the registration dataset (n=55) of RET-mutant medullary thyroid cancer (MTC) patients who had ..."
Published: Sep 29th, 2019 2:26 PM
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated ...
"LIBRETTO-001 is the largest trial ever reported in RET-altered cancer patients. - 56 percent objective response rate (ORR) in the registration dataset ..."
Published: Sep 29th, 2019 2:26 PM
Lilly (LLY) Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily ...
"Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral ..."
Published: Sep 29th, 2019 2:26 PM
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated ...
"Selpercatinib therapy also resulted in robust biochemical response rates (BRR) for serum tumor markers calcitonin (91% BRR) and carcinoembryonic ..."
"... GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer."
Published: Sep 28th, 2019 12:33 PM
Blueprint Medicines Corporation (NASDAQ:BPMC) on Focus After Report of Less Shorts
"It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; ..."
Published: Sep 28th, 2019 11:37 AM
Canada Pension Plan Investment Board Reduces Stake in Exelixis, Inc. (NASDAQ:EXEL)
"... prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer."
Published: Sep 27th, 2019 8:02 PM
Volleyball Knee Pads Market by Major Players, Volume, Demand, Market Dynamic Forces ...
"Previous Post Medullary Thyroid Cancer Market Analysis, Forecast of Business Revenue, Size, Leading Competitors and Growth Trends. Next Post ..."
Published: Sep 27th, 2019 8:02 PM
Global and Regional Malignant Glioma Market Status, Development and Opportunities in 2019-2024
"Malignant Glioma Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic methods."
Published: Sep 27th, 2019 5:03 PM
Medullary Thyroid Cancer Analysis Market: 2019 Global Opportunities, Share, Key Players, Size ...
"Medullary Thyroid Cancer Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic ..."
Published: Sep 27th, 2019 10:41 AM
Global Radioactive Iodine Ablation Therapy Market research lucrative opportunities by 2018-2028 ...
"According to WHO thyroid cancer is differentiated into papillary and ... Radioactive iodine ablation therapy can destroy the thyroid gland and any ... cancer cells do not take up iodine, such as medullary and anaplastic thyroid cancers."
Published: Sep 26th, 2019 7:18 PM
Angiopoietin 1 Receptor Market- Drug Profile, Pipeline Review, Companies Involved in ...
Head-To-Head Review: Exelixis (NASDAQ:EXEL) and National Research (NASDAQ:NRC)
"... the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, ..."
Published: Sep 25th, 2019 7:18 PM
Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach
"Eli Lilly announced that it had achieved positive results from a phase 1/2 study using the drug selpercatinib to treat RET fusion-positive non-small cell ..."
Published: Sep 25th, 2019 4:18 PM
What to look out for at ESMO 2019
"At the start of the year, when Eli Lilly (NYSE: LLY) bought Loxo Oncology, the potential of its first-in-class oral RET inhibitor LOXO-292 was central to ..."
Published: Sep 24th, 2019 8:23 PM
Hitchwood Capital Management LP Increased Position in Illumina (ILMN); Wellington Management ...
"... AND LOXO-292 (RET); 13/04/2018 – BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND ..."
Published: Sep 24th, 2019 8:02 PM
Trexquant Investment LP Lifted Its Position in Monro (MNRO) as Valuation Rose; Illumina (ILMN ...
"... LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 13/04/2018 – BRISTOL-MYERS SQUIBB & ILLUMINA IN IMMUNOTHERAPY PACT; 10/04/2018 ..."
Published: Sep 24th, 2019 5:18 PM
Sarepta Therapeutics (SRPT) Shareholder Botty Investors Has Lifted Its Stake; Shareholder Atlanta ...
"... DIAGNOSTIC VERSION OF TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 13/04/2018 – Bristol-Myers Squibb and ..."
Published: Sep 24th, 2019 5:15 PM
Jennison Associates Upped Illumina (ILMN) Position By $109.13 Million; Fate Therapeutics (FATE ...
"$1.02; 10/04/2018 – ILLUMINA INC – LOXO ONCOLOGY TO UTILIZE A ... TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 ..."
Published: Sep 24th, 2019 10:52 AM
$0.54 EPS Expected for Cleveland-Cliffs Inc. (CLF); Her Majesty The Queen In Right Of The ...
"... AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS; 24/05/2018 – Kaskela Law LLC Announces Investigation of ..."
Published: Sep 23rd, 2019 11:37 PM
Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And ...
"Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing ..."
Published: Sep 23rd, 2019 11:37 PM
Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And ...
"Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing ..."
Published: Sep 23rd, 2019 7:51 PM
Chesley Taft & Associates Holding in Air Products & Chemicals (APD) Has Raised as Valuation ...
"... COMPANION DIAGNOSTIC VERSION OF TRUSIGHT TUMOR 170 FOR LAROTRECTINIB (NTRK) AND LOXO-292 (RET); 24/04/2018 – ILLUMINA ..."
Published: Sep 23rd, 2019 7:30 PM
Lilly, Bayer's tumor-agnostic cancer drug gets European nod
"Earlier this month, Lilly presented data for another drug, LOXO-292 (selpercatinib), at the World Conference on Lung Cancer, which also took place in ..."
Published: Sep 23rd, 2019 7:30 PM
Lilly, Bayer's tumor-agnostic cancer drug gets European nod
"Another company, Blueprint Medicines, has a competing RET inhibitor in development, BLU-667 (pralsetinib). Analysts have remarked that the ..."
Published: Sep 23rd, 2019 10:41 AM
Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019
"Selpercatinib is being investigated in RET fusion-positive cancers across tumor types and RET-mutant medullary thyroid cancer (MTC). RET fusions ..."
Published: Sep 23rd, 2019 10:41 AM
Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019
"RET-altered thyroid cancer data for selpercatinib[1] (LOXO-292) from the Phase 1/2 LIBRETTO-001 study to be featured in late-breaking oral ..."
Published: Sep 22nd, 2019 7:16 PM
Biofrontera AG (BFRA) and Exelixis Inc. (NASDAQ:EXEL) Comparison side by side
"In addition, it is developing Ameluz for the treatment of basal cell carcinoma; ... of patients with progressive, metastatic medullary thyroid carcinoma."
Published: Sep 22nd, 2019 1:18 PM
Thyroid Cancer Awareness Month
"And, unlike many other cancers, the mortality rate for thyroid cancer has ... Papillary (and variants), Follicular (including Hurthle Cell), Medullary and ..."
Published: Sep 20th, 2019 9:00 PM
Medullary Thyroid Cancer Drugs Market Size 2019: Opportunities and Forecasts 2025
"The Medullary Thyroid Cancer Drugs market study formulated by Dataintelo, presents a detailed analysis of the influential trends prevailing in this ..."
Published: Sep 20th, 2019 4:18 PM
Patients Who Use Natpara Say They are Suffering After Recall
"In this segment, we talk to Becky Buckman who took part in the clinical trials for Natpara and says the drug is a lifesaver. She is now part of a group of ..."
Published: Sep 20th, 2019 4:07 PM
Drugs in the Pipeline: Non-Small-Cell Lung Cancer
"Several promising drugs for the treatment of lung cancer have been ... papillary thyroid cancer (PTC), RET-mutant medullary thyroid cancer (MTC), ..."
Published: Sep 20th, 2019 2:48 PM
FDA approves Rybelsus (semaglutide), the first GLP-1 analog treatment available in a pill for ...
"These may be symptoms of thyroid cancer. ... It is not known if Rybelsus will cause thyroid tumors or a type of thyroid cancer called medullary thyroid ..."
Published: Sep 20th, 2019 10:41 AM
CHMP Issues Positive Opinion to Expand Trulicity (dulaglutide) Label to Include Results from ...
"It is not known if Trulicity will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Patients should not ..."
Published: Sep 19th, 2019 2:26 PM
Orphan Drugs Market Key Business Opportunities and Precise Outlook by 2027 | Biogen, Bristol ...
"Based on disease the market is segmented into Hodgkin lymphoma, ... 1 (GD1), Metastatic medullary thyroid carcinoma, Advanced gastric cancer or ..."
Published: Sep 19th, 2019 1:52 PM
Tmunity Announces Presentation at the Cantor Fitzgerald 2019 Global Healthcare Conference
"PHILADELPHIA--(BUSINESS WIRE)--Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving ..."
Published: Sep 19th, 2019 9:56 AM
Thyroid Cancer: Knowing The Facts This Thyroid Cancer Awareness Month
"A small gland located at the base of the neck, the thyroid is part of our ... People with a family history of thyroid cancer, especially medullary thyroid ..."
Published: Sep 19th, 2019 3:56 AM
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Allianz Asset Management GmbH
"... commercialization of new medicines to treat cancers in the United States. ... of patients with progressive and metastatic medullary thyroid cancer."
Published: Sep 18th, 2019 6:56 PM
Selpercatinib Promising in RET Fusion-Positive NSCLC
"Treatment with selpercatinib (LOXO-292) was associated with high objective response rate (ORR) in heavily pretreated patients with RET ..."
Published: Sep 18th, 2019 6:56 PM
Selpercatinib Promising in RET Fusion-Positive NSCLC
"... platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 therapy; RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, ..."
Published: Sep 18th, 2019 1:41 PM
'It's really scary': Recall of Natpara leaves patients in limbo
"Natpara was recalled this month because tiny pieces of rubber from the injector were found in some vials of the drug, which could contaminate the ..."
Published: Sep 18th, 2019 6:23 AM
NorCal patients live in fear after parathyroid drug recall
"People suffering from a rare, but potentially deadly disease are now living in fear after their life-saving medication called Natpara was suddenly ..."
Published: Sep 16th, 2019 9:33 PM
Papillary Thyroid Cancer Market Will Make a Huge Impact in Near Future
"Follicular cancer, medullary cancer, and anaplastic cancer are other types of thyroid cancers. The prevalence rate of papillary thyroid cancer is 0.5-10 ..."
Published: Sep 16th, 2019 7:30 PM
How a Once-Weekly Injection Can Help Manage Type 2 Diabetes
"It is unknown whether BYDUREON BCise causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) in humans, as the human ..."
Published: Sep 16th, 2019 4:30 PM
Exelixis (NASDAQ:EXEL) and Vitality Biopharma (NASDAQ:VBIO) Head-To-Head Comparison
"... and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ ..."
Published: Sep 16th, 2019 10:18 AM
Radioactive Iodine Ablation Therapy Market Pegged for Robust Expansion During 2018 - 2028
"Increasing mortality & morbidity caused due to thyroid cancer and other ... do not take up iodine, such as medullary and anaplastic thyroid cancers."